Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 10/20 | 0.50 |
| ▸ | BCHE | P06276 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129259 | 0.79 | LMNA (0.48) | ACHELMNAMAPK1KMT2ANPSR1 | |
| SCHEMBL486200 | 0.77 | RAB9A (0.72) | RAB9AACHEBCHELMNAGLA | |
| SCHEMBL8867798 | 0.77 | RAB9A (0.59) | RAB9AACHEBCHELMNAGLA | |
| Phenyl Dimethylcarbamate SCHEMBL491227 | 0.77 | RAB9A (0.78) | RAB9AACHEBCHELMNAGLA | |
| SCHEMBL6972597 | 0.76 | HSD17B10 (0.40) | LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9817182 | 0.75 | ELANE (0.49) | ACHELMNAKMT2ANPSR1MEN1 | |
| SCHEMBL7219935 | 0.75 | ELANE (0.52) | — | |
| SCHEMBL128694 | 0.75 | ACHE (0.49) | RAB9AACHELMNAGLAMAPK1 | |
| SCHEMBL5396445 | 0.75 | ACHE (0.43) | RAB9AACHEBCHEMAPK1KMT2A | |
| SCHEMBL3597111 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-4692530-A | Chemical agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1987-09-08 | — | — | US | claimed |
| US-9309187-B2 | EP2 receptor agonists | TAKEDA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150080400-A1 | Novel EP2 Receptor Agonists | TAKEDA GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2844638-A1 | NOVEL EP2 RECEPTOR AGONISTS | Takeda GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164326-A1 | NOVEL EP2 RECEPTOR AGONISTS | TAKEDA GMBH (DE) | 2013-11-07 | — | — | WO | disclosed |
| EP-1565475-B1 | DIAZINOPYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1565475-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| WO-2004046152-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN LA ROCHE AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-5436267-A | An O-(N-2-carbamylphenyl)-heterocyclic oxime; insecticides; fungicides; miticides; nematocides; plant growth regulators; herbicides; viricides; attractants | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| US-4692530-A | Chemical agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | RAB9A 115/4885ACHE 13/4885BCHE 62/4885 |
| US-20050261284-A1 | Diazinopyrimidines | MAPK6, MAPK1, MAP2K6 | RAB9A 3657/4885ACHE 3896/4885BCHE 4688/4885 |
| US-20150080400-A1 | Novel EP2 Receptor Agonists | PTGER1, PTGER2, PTGER4 | RAB9A 2704/4885ACHE 1957/4885BCHE 3874/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | RAB9A 1955/4885ACHE 4868/4885BCHE 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.